Aaron Nizam

Dr. Aaron Nizam

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2021 in JCO Precision Oncology
Verified
Journal Article
Open access
BBBethany Bustamante
Bethany Bustamante
RSRisha Sinha
Risha Sinha
BRBriana Rice
Briana Rice
ANAaron Nizam
Aaron Nizam
WSWeiwei Shan
Weiwei Shan
MFMarina Frimer
Marina Frimer
PURPOSE: Homologous recombination deficiency, identified by homologous recombination deficiency gene alterations or high percentage of genome-wide loss of heterozygosity (gLOH), is associated with improved prognosis, platinum sensitivity (PS), and poly (ADP-ribose) polymerase inhibitor response in high-grade ovarian cancer. Since the copy number–high (CN-H) endometrial cancer molecular subtype (EC-MS) shares molecular features with high-grade ovarian cancer, our aim was to assign EC-MS on the basis of comprehensive genomic profiling (CGP) results and evaluate the gLOH status with clinical behavior of EC. METHODS: Eighty-two epithelial EC tumor tissues were sequenced by hybrid capture–based CGP, and results were used to assign EC-MS (ultramutated, microsatellite instability–high, CN-low; CN-high). Retrospective chart review established clinical characteristics, including PS. Relationships of PS, EC-MS, gene alterations, and gLOH were assessed statistically. RESULTS: PS and EC-MS of CN-H showed statistically significant difference in overall survival (OS). Most notably, when the CN-H EC-MS was subcategorized by gLOH status, there was a significant difference in OS with gLOH-H being associated with longer survival. Cox semi-proportional hazard modeling showed that gLOH, stage, and race were significant in modeling OS. CONCLUSION: The method of assigning EC-MS by CGP demonstrates similar clinical features to previous reports of EC-MS assigned by other methods. CGP can also assess gLOH status with gLOH-H most commonly seen in CN-H tumors. CN-H, gLOH-H patients showed significantly improved OS (hazard ratio, 0.100 [0.02-0.51 95% CI]). Thus, gLOH status may be a meaningful prognostic biomarker within the CN-H tumors and possibly across EC-MS.

22 November 2019 in Diagnostics
Verified
Journal Article
Open access
PDF file
ANAaron Nizam
Aaron Nizam
BBBethany Bustamante
Bethany Bustamante
WSWeiwei Shan
Weiwei Shan
KSKarin K. Shih
Karin K. Shih
JWJill S. Whyte
Jill S. Whyte
GGGary L. Goldberg
Gary L. Goldberg
Background: Carcinosarcoma of the ovary (CSO) is a rare and aggressive variant of ovarian cancer. Due to the rare nature of the disease there is insufficient evidence to make recommendations regarding standard management and overall prognosis. Methods: An Institutional Review Board-approved study identified all our patients with CSO between January 2011 and May 2018. Demographic and outcome measures were abstracted from the medical records and tumor board files. Cox proportional hazard models, log rank tests, and comparisons of means were used to calculate significance (p < 0.05). Results: 27 women with CSO were identified. The median age at diagnosis was 65 years (range 48–91). Five women (18%) presented with early stage disease (Stage I or II) and 22 patients (82%) presented with late stage III or IV disease. Twenty patients (74%) received intravenous platinum-based combination chemotherapy. Seven patients did not receive chemotherapy during their treatment course. The median overall survival was 23 months (range 2–68 months). Overall survival was not significantly worsened by the stage of disease at diagnosis. There was no difference in survival based on the age at diagnosis, tobacco status or ethnicity (p > 0.05). Conclusion: This is one of the largest single institution experiences with CSO. The majority of our patients presented with advanced stage disease and received adjuvant platinum-based chemotherapy after cytoreductive surgery. The median overall survival of 23 months was not affected by the stage of the disease. The optimal management of this rare disease needs further study with collaborative, prospective multi-institutional trials.

1 May 2018 in Journal for Healthcare Quality
Verified
Journal Article
Closed access
DNDeepti Nahar
Deepti Nahar
ANAaron Nizam
Aaron Nizam
MFMonique Farrow
Monique Farrow
ARAndrea Restifo
Andrea Restifo
MNMichael Nimaroff
Michael Nimaroff
Venous thromboembolic events (VTE) occurring in the postoperative period are serious yet preventable conditions. Multiple studies have demonstrated that the risk of postoperative VTE can be successfully reduced with mechanical prophylaxis and/or chemoprophylaxis. Patients are often noncompliant with mechanical prophylaxis in the postoperative period. We performed a prospective nonrandomized controlled study to determine if providing an educational pamphlet would increase knowledge and compliance with mechanical VTE prophylaxis. Patients receiving the educational pamphlet were more likely to rate their knowledge of VTE prophylaxis as “very good” when compared to the control group (73.1% vs. 30.2%, p < .001). Patients were also more likely to be compliant with mechanical prophylaxis in the educational group (53.9% vs. 30.2%, p = .014). Our study demonstrated that providing a simple educational pamphlet increased patient knowledge regarding VTE prophylaxis and increased compliance with mechanical prophylaxis.

1 August 2020 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
ANAaron Nizam
Aaron Nizam
AMAndrew W. Menzin
Andrew W. Menzin
JWJill S. Whyte
Jill S. Whyte
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis has been described in increasing frequency in association with benign, mature ovarian teratoma. Affected patients typically present with paraneoplastic limbic encephalitis with flu-like symptoms followed by altered mental status, acute psychiatric symptoms, seizures and amnesia. These symptoms can rapidly progressive if not treated aggressively with surgical resection. Profound neurological symptoms may require immunotherapy. We present a case of anti-NMDA receptor encephalitis associated with a malignant immature teratoma in which symptoms were refractory to surgical management and initial immunotherapy. A complete neurologic response was only seen after initiating adjuvant chemotherapy. Anti-NMDA receptor encephalitis has rarely been described with immature ovarian teratomas. In these cases, a complete response may not be observed until systemic chemotherapy is started.

1 March 2026 in Cancer Research Communications
Verified
Journal Article
Open access
CCCharlie Chung
Charlie Chung
BYBrian Yueh
Brian Yueh
SSSanthilal Subhash
Santhilal Subhash
OEOnur Eskiocak
Onur Eskiocak
ANAaron Nizam
Aaron Nizam
SBSemir Beyaz
Semir Beyaz
High-grade endometrial cancers (HGEC) disproportionately affect women of African ancestry and often resist currently available immunotherapies. Defining the mechanisms driving this resistance is impeded by a lack of preclinical models that preserve ancestral diversity and patient-matched tumor–immune interactions without confounding alloreactivity. To address this gap, we established a biobank of 85 endometrial cancer patient-derived organoids (PDO) from a diverse cohort, enriched for HGEC PDOs from African American patients, and paired these with autologous immune cells to develop a patient-specific PDO–immune cell coculture platform with real-time live-imaging readouts. Using this system, we found that HGECs evade immune surveillance through pronounced suppression of major histocompatibility complex (MHC) class I and II antigen presentation pathways relative to their matched normal counterparts. Restoring antigen presentation, either by IFNγ stimulation or epigenetic reprogramming via enhancer of zeste homolog 2 inhibition, rescued MHC expression and sensitized HGEC PDOs to autologous T cell–mediated cytotoxicity. Extending the platform to NK cells revealed heightened killing of low–MHC-I PDOs. Consistent with clinical observations, mismatch repair (MMR)-deficient HGEC PDOs exhibited stronger immune engagement than their MMR-proficient counterparts. Finally, this platform enabled evaluation of the safety and efficacy of emerging immunotherapies, including protease-activatable bispecific T-cell engagers and EGFR-targeted chimeric antigen receptor T cells. Together, this sustainable, scalable, ancestrally diverse autologous PDO–immune cell coculture platform offers a robust resource for dissecting immune evasion mechanisms and accelerating the development of new immunotherapies to address disparities in endometrial cancer outcomes. Significance: The efficacy of immunotherapy for HGECs remains limited, partly because current preclinical models poorly capture tumor heterogeneity and patient-specific immune microenvironment. These cancers disproportionately affect women of African ancestry, yet most studies rely on European ancestry samples. We developed an autologous PDO and immune cell coculture platform from patients of diverse ancestries. This system enables patient-level analysis of tumor–immune interactions to support development and testing of novel immunotherapeutic strategies.

17 September 2021 in American Journal of Obstetrics & Gynecology MFM
Verified
Journal Article
Closed access
ANAaron Nizam
Aaron Nizam
MNMichael L. Nimaroff
Michael L. Nimaroff
AMAndrew W. Menzin
Andrew W. Menzin
GGGary L. Goldberg
Gary L. Goldberg
SMSantiago J. Miyara
Santiago J. Miyara
EMErnesto Molmenti
Ernesto Molmenti